A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antipsychotic Monotherapy in Adults With Schizophrenia.

Trial Profile

A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antipsychotic Monotherapy in Adults With Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Paliperidone (Primary) ; Paliperidone (Primary) ; Aripiprazole; Haloperidol; Olanzapine; Quetiapine; Risperidone
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms PROSIPAL
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 04 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jun 2012 Actual patient number changed from 769 to 783 and additional trial location (Italy) added as reported by ClinicalTrials.gov.
    • 07 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top